 (2).png "India Gets Its First Bluetooth CGM as Tracky Redefines Diabetes Monitoring")
Tracky, a brand of DrStore Healthcare Services and a health tech startup, launched India's first Bluetooth Continuous Glucose Monitor
At the retail price previously authorized by the National Pharmaceutical Pricing Authority ( NPPA), Torrent Pharmaceuticals has been permitted to move the manufacturing of its combination medication for nutritional
 (1).png "Dr Reddy's Partners with Alvotech to Expand in Oncology Biosimilars")
Dr Reddy's Laboratories has made a strategic partnership with global biotechnology company Alvotech for the co-development and commercialization of a biosimilar of Keytruda
A significant drop is being seen in the prices of active pharmaceutical ingredients (API) used for manufacturing drugs, bringing relief to India's pharmaceutical industry. China is largely depended upon the pharma industry for sourcing APIs
 (1).png "CDSCO Clears Phase III Trial of Tetanus Vaccine in Pregnant Women")
The major boost for maternal immunization in New Delhi, the Subject Expert Committee (SEC) on Vaccines of the Central Drugs Standard Control Organisation
An agreement has been reached between BioNTech and Bristol Myers Squibb for the worldwide co-development and co-commercialization of BioNTech's investigational bispecific antibody BNT327 across a variety of solid tumor types.
 (1).png "NPPA Regulates 41 Drug Combinations to Curb Healthcare Costs")
The National Pharmaceutical Pricing Authority (NPPA) has fixed the retail price ceilings on 41 combinations of drugs, including 18 types of Boehringer Ingelheim's
The Authentication Solution Providers’ Association (ASPA) ahead of World Anti-Counterfeiting Day, has commissioned the second edition of its flagship industry report, ‘State of Counterfeiting in India – 2025
 (1).png "Allarity Begins Phase 2 Trial of Stenoparib in Advanced Ovarian Cancer")
Allarity Therapeutics, a Phase 2-stage biopharmaceutical with activities in Copenhagen and Boston, has formally enrolled its first patient in its newly launched Phase 2 trial
Aumolertinib (Aumseqa) has been approved by the Medicines and Healthcare products Regulatory Agency (MHRA) for adult patients with non-small cell lung cancer (NSCLC).
.jpg)
, CDSCO.jpg "Fostering a Quality Culture in the Pharmaceutical Industry")